[Treatment of bone metastases].

Treatment of bone metastases differs depending on whether the original cancer was diagnosed, whether it is hormone sensitive or chemosensitive, whether metastases are exclusively found in bones and thus unique, or multiple, whether they also occur in viscera and depending on the diathesis. In the last few years, treatment has benefited from a better knowledge of the efficacy of bisphosphonates, radioisotopes, percutaneous vertebroplasty and the development of new hormone therapies and chemotherapies. Given the uncertain life prognosis in the short or longer term, it remains true that cautious use of these methods is essential to reduce as far as possible the number and duration of hospitalizations.

Rheumatological management of patients with hemophilia. Part II: Muscle hematomas and pseudotumors.

Although less common than hemarthroses, muscle hematomas nearly always threaten limb function and can threaten life. Their treatment is not as well standardized as that of hemarthrosis but also rests on clotting factor replacement, prevention of contractures, and rehabilitation. Pseudotumors raise even greater treatment challenges and usually require surgery in adults.

Rheumatological management of patients with hemophilia. Part 1: joint manifestations.

The advent of factor VIII and IX replacement therapy has radically changed the physiognomy of hemophilia. In patients with no inhibitors, early replacement therapy shortens the immobilization and decreases the structural and functional alterations related to recurrent hemarthrosis. Routine prophylactic replacement therapy before or after the first episode of hemarthrosis is still rarely used in France.